Celgene lands Orphan designation for sotatercept

Celgene (CELG +0.8%) gets an Orphan designation for sotatercept in
beta-thalassemia intermedia and major. (FDA)

From other sites
Comments (5)
  • karmaswimswami
    , contributor
    Comments (125) | Send Message
    Excellent company. I have been long for years. It increasingly appears that they may try to get into the stem cell side of things as well. Cramer keeps calling Celgene, Gilead, Biogen Idec and Regeneron the four horsemen of pharma. I'm not so sure about Biogen, but the others? Yes.
    6 Dec 2013, 02:01 PM Reply Like
  • Cora Schlesinger
    , contributor
    Comments (1185) | Send Message
    Must have included Amgen there. Never had any regrets about buying CELG.
    6 Dec 2013, 03:45 PM Reply Like
  • john parlitsis
    , contributor
    Comments (6) | Send Message
    Been with CElg for the last 5 years...I think it will prove itself all the way to the bank! Great pipeline of things to come! Stay with a winner..J.P.
    6 Dec 2013, 06:45 PM Reply Like
  • chicagomary
    , contributor
    Comments (413) | Send Message
    Have you noticed recent activity again in
    $CELGZ? The next payout may be half of first payment,but we are closer to % payout if Abraxane meets the larger sales target. Staying long.
    8 Dec 2013, 09:32 AM Reply Like
  • hneumann
    , contributor
    Comments (630) | Send Message
    I wonder if the rising number of expensive drugs is sustainable with the rising percentage of older people. Healthcare costs could get out of hand soon, at least for the insurances.
    6 Dec 2013, 08:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs